Bookkeeping

Philip R. Lane: Disinflation in the euro area: an update

Retrieved on: 
Thursday, April 18, 2024
Element, Reproduction, SAFE, Speech, Conference, Growth, Brookings Institution, Disinflation, Finance, Projection, Exercise, ECB, Real, Risk, Frankfurt, Bank, SPF, Policy, Communication, ILS, HICP, OIS, DFR, GDP, The, APP, Watcher, Bangladesh Technical Education Board, Probability, Swings, Fiscal, Acceleration, Goethe University Frankfurt, Personal ordinariate, PEPP, CTS, European Central Bank, Fear, Bookkeeping

Stock market development and familiarity (language and distance) are considered key determinants for home bias.

Key Points: 
  • Stock market development and familiarity (language and distance) are considered key determinants for home bias.
  • The literature neglects however that investors often invest in foreign funds domiciled in financial centers.

EQS-News: Aumann significantly increases revenue in 2023, doubles EBITDA and achieves new record figures for order intake and liquidity

Retrieved on: 
Wednesday, April 10, 2024
Automation, Annual, Share repurchase, Annual general meeting, Growth, Supervisory board, Annual report, Record, Bookkeeping

Aumann significantly increases revenue in 2023, doubles EBITDA and achieves new record figures for order intake and liquidity

Key Points: 
  • Aumann significantly increases revenue in 2023, doubles EBITDA and achieves new record figures for order intake and liquidity
    The issuer is solely responsible for the content of this announcement.
  • Aumann significantly increases revenue in 2023, doubles EBITDA and achieves new record figures for order intake and liquidity
    Aumann AG ("Aumann", ISIN: DE000A2DAM03), a leading manufacturer of automation solutions for electromobility, successfully continued its profitable growth trajectory in the 2023 financial year.
  • Aumann's revenue grew dynamically by 34.5% to €289.6 million, with revenue in the E-mobility segment increasing particularly strongly by 61.2% to €229.1 million.
  • Order intake exceeded the successful previous year by 14.9% and reached a new record in the company’s history at €339.4 million.

EQS-News: Semperit strengthened for further growth after transformation year – earnings 2023 still burdened by sold medical business

Retrieved on: 
Wednesday, April 10, 2024
Informal economy, Automation, EUR, Annual, Health, Sale, Acquisition, Food, SIA, Industrial, HARPS, Mining, Bookkeeping

Earnings after tax from continued operations were positive at EUR 24.9 million, while the loss from the medical business, which has been sold, had a significant negative impact as expected.

Key Points: 
  • Earnings after tax from continued operations were positive at EUR 24.9 million, while the loss from the medical business, which has been sold, had a significant negative impact as expected.
  • Earnings development 2023 in detail:
    The continued operations of the Semperit Group recorded revenue of EUR 721.1 million (–7.5%) in the 2023 financial year.
  • Also considering the proceeds from the sale of Examination Operations (medical business), results in EUR 111.5 million (previous year: EUR –2.8 million).
  • Overview of the main financial figures of the financial year 2023:
    Key figures of the Semperit Group, in EUR million

The Simply Good Foods Company Reports Fiscal Second Quarter 2024 Financial Results and Updates Full Fiscal Year 2024 Net Sales and Adjusted EBITDA Outlook

Retrieved on: 
Thursday, April 4, 2024
Health, Convenience, Growth, EPS, Tax, International, Internet, Acquisition, G&A, Depreciation, Adjustment, IRI, Investment, Interest, GAAP, Earnings per share, Marketing, Advertising, Bookkeeping

"Simply Good Foods second quarter results were led by continued Quest growth, as well as strong gross margin performance," said Geoff Tanner, President, and Chief Executive Officer of Simply Good Foods.

Key Points: 
  • "Simply Good Foods second quarter results were led by continued Quest growth, as well as strong gross margin performance," said Geoff Tanner, President, and Chief Executive Officer of Simply Good Foods.
  • In the second quarter of fiscal 2024, total Simply Good Foods retail takeaway in the combined U.S. measured and unmeasured channels increased about 3%.
  • Year-to-Date Second Quarter 2024 Highlights vs. Year-to-Date Second Quarter 2023(1)
    Net sales increased $23.4 million, or 3.9%, to $620.9 million.
  • Due to lower than anticipated Atkins consumption in the second quarter of fiscal 2024, the Company has updated its full year fiscal 2024 outlook.

Stifel Financial Earns Credit Upgrade

Retrieved on: 
Tuesday, April 2, 2024
Risk management, S&P Global Ratings, Eaton Partners, Broker-dealer, S&P, SF, Bookkeeping

ST. LOUIS, April 02, 2024 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that S&P Global Ratings (S&P) has raised its long-term rating on Stifel, reflecting sound credit and interest rate risk management.

Key Points: 
  • ST. LOUIS, April 02, 2024 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that S&P Global Ratings (S&P) has raised its long-term rating on Stifel, reflecting sound credit and interest rate risk management.
  • Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries.
  • Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners and Miller Buckfire business divisions; Keefe, Bruyette & Woods, Inc.; and Stifel Independent Advisors, LLC; in Canada through Stifel Nicolaus Canada Inc.; and in the United Kingdom and Europe through Stifel Nicolaus Europe Limited.
  • Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions.

Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
ACT, Cancer, COVID, Growth, History, Clinical trial, Genomics, Bookkeeping

HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.

Key Points: 
  • HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.
  • Revenue from continuing operations of US$5.4 million in the fourth quarter 2023, an increase of 90.8% as compared to the fourth quarter 2022.
  • Adjusted EBITDA from continuing operations of US$(6.2) million in the fourth quarter 2023.
  • Adjusted net loss attributable to equity shareholders of Prenetics was US$(28.4) million for the year ended December 31, 2023.

XBP Europe Holdings, Inc. Reports Full Year 2023 Results

Retrieved on: 
Monday, April 1, 2024
Capital expenditure, Growth, TCV, Bill, Operating cost, Sale, XBP, Adjustment, Bookkeeping

LONDON and SANTA MONICA, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- XBP Europe Holdings, Inc. (“XBP” or the “Company”) (NASDAQ: XBP), a pan-European integrator of bills and payments and related solutions and services seeking to enable the digital transformation of its clients, announced today its financial results for the full year ended December 31, 2023.

Key Points: 
  • “We start the year as a newly listed public company, having completed our long-awaited business combination towards the very end of 2023.
  • We will keep our employees and the investor community apprised of our progress in the coming weeks and months,” said Andrej Jonovic, Chief Executive Officer of XBP.
  • Net Loss: Net loss for 2023 was $11.0 million, compared with a net loss of $7.9 million in 2022.
  • Adjusted EBITDA(1): Adjusted EBITDA for 2023 was $11.6 million, a decrease of 20.0% compared to $14.5 million in 2022.

Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023

Retrieved on: 
Wednesday, March 27, 2024
Financial statement, Growth, Infertility, International, IVF, Travel, EDT, Acquisition, Laboratory, Consumables, Adjustment, Investment, Depreciation, Analysis, Marketing, Hand, Bookkeeping

Results of Operations for the Year ended December 31, 2023

Key Points: 
  • Results of Operations for the Year ended December 31, 2023
    Hamilton Thorne sales increased 16% to $67,225,476 for the year-ended December 31, 2023, an increase of $9,047,409 from $58,178,067 during the previous year.
  • Consumable sales in 2023 outpaced the Company’s overall growth despite being affected by the recall of certain products by one of the Company’s contract manufacturers.
  • We are expecting first quarter 2024 reported revenues of between $19.0 to 19.4M, with organic growth for the quarter of approximately 8%.
  • Financial Statements and accompanying Management Discussion and Analysis for the periods are available on www.sedar.com and the Hamilton Thorne website.

Kelso Technologies Inc. Financial Results for the Year Ended December 31, 2023

Retrieved on: 
Tuesday, March 26, 2024
Tax, McKinsey & Company, Growth, AAR, Patent application, Patent, Intelligence, COVID-19, Advanced driver-assistance system, Travel, Research, ADAS, Wilderness, Policy, Black–Scholes model, Emergency, Adjustment, Safety, Forestry, Telecommunications, Engineering, Mining, Bookkeeping

The Company had income tax payable of $10,024 at December 31, 2023 compared to $30,626 at December 31, 2022.

Key Points: 
  • The Company had income tax payable of $10,024 at December 31, 2023 compared to $30,626 at December 31, 2022.
  • Total assets of the Company were $9,703,271 as at December 31, 2023 compared to $12,147,143 as at December 31, 2022.
  • Net assets of the Company were $8,720,248 as at December 31, 2023 compared to $10,781,672 as at December 31, 2022.
  • The Company had no interest-bearing long-term liabilities or debt as at December 31, 2023 or December 31, 2022.

Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023

Retrieved on: 
Wednesday, March 20, 2024
Financial statement, Prior, Bank statement, Annual report, Bookkeeping

The restatements correct errors involving the calculation of capitalized interest, valuation of inventories, and certain other adjustments related to previously divested businesses reflected in the Prior Financial Statements.

Key Points: 
  • The restatements correct errors involving the calculation of capitalized interest, valuation of inventories, and certain other adjustments related to previously divested businesses reflected in the Prior Financial Statements.
  • The Company restated FY21 opening retained earnings to account for the cumulative effect of the above restatements.
  • The Company restated the presentation of certain operating costs and expenses of continuing operations and discontinued operations affecting FY22 and FY21.
  • The 2023 Annual Report on Form 10-K and supplementary financial data package can be found in the Investors section of the Lifecore website at https://ir.lifecore.com/ .